AUTHORS
Mansi Ramesh Shah, MD, Aniko Szabo, PhD2, Natasha Harpalani, MD3, Krystal Mathew, MD4, Manpreet Saini, MD5, Kishan Bhatt, MA6, Sabarinath Venniyil Radhakrishnan, MD7, Sharmilan Thanendrarajan, MD8, Maurizio Zangari, MD9, Frits van Rhee, MD, PhD10, Binod Dhakal, MD, MS11, Suzanne Lentzsch, MD, PhD12, Divaya Bhutani, MD13, Anita D'Souza, MD14, Meera Mohan, MD, MS15, Rajshekhar Chakraborty, MD16, Carolina D Schinke, MD17
AFFILIATIONS
1 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
2 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
3 Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
4 Data Science Institute, Milwaukee, Wisconsin, United States
5 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
6 Columbia University Irving Medical Center, New York, New York, United States
7 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
8 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
9 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
10 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
11 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
12 Columbia University Irving Medical Center, New York, New York, United States
13 Columbia University Irving Medical Center, New York, New York, United States
14 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
15 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 Columbia University Irving Medical Center, New York, New York, United States
17 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
ABSTRACT
Introduction: Infections and cytopenias are major toxicities associated with B-cell maturation antigen (BCMA)-targeted bispecific antibodies (BsAbs) in multiple myeloma (MM); however, real-world data characterizing the incidence and trajectory of cytopenias and their temporal relationship with infection remain limited.
Methods: We conducted a multicenter retrospective cohort study of patients with relapsed/refractory MM treated with BCMA-targeting BsAbs (teclistamab, elranatamab, or linvoseltamab) from 2019 to 2025. Cytopenias were graded per NCI CTCAE V5, assessed from treatment start to 30 days after the last BsAb dose, with all complete blood count data captured. We evaluated the cumulative incidence and prevalence of grade 3-4 (G3+) cytopenias over time and used univariable and multivariable models to identify predictors. High-risk (HR) cytogenetics was defined by del(17p), t(4;14), t(14;16), t(14;20), or gain/amp(1q).
Results: The cohort included 187 patients with a median age of 71 years; 49% female; 30% Black. The median prior lines of therapy were 4 (range, 1-12). 77% of patients had triple-class refractory MM, and 67% had penta-refractory MM. 76% of patients had at least one prior ASCT, 22% had received a prior BCMA-targeted therapy, and 7.6% had plasma cell leukemia. HR cytogenetics were present in 60% of patients. The median progression-free survival on BsAb therapy was 10 months (95% CI, 7.4-17), 8.5% were still on treatment at 2 years, and median overall survival was 19 months (95% CI, 16-30).
At baseline, 49% of patients had anemia, with G3 in 15%. Additionally, 16% had neutropenia, including 5% with G3+. Lymphopenia was observed in 47%, with 31% G3+, while 28% showed thrombocytopenia, and 17% of these cases were G3+. The cumulative incidence of G3+ cytopenias at 1, 6, and 12 months, respectively, was: anemia, 35%, 38%, and 40%; neutropenia 23%, 38%, and 40%; lymphopenia 70%, 71%, and 73%; and thrombocytopenia 26%, 29%, and 29%. Among patients still on treatment, the kinetics of G3+ cytopenia differed by type: anemia peaked early (18% at day 4), then declined to 5% at day 30 and 0% at day 365, while thrombocytopenia was 19% at day 2 and then declined to 10% at day 30 and 3% at day 365.
Grade 3+ lymphopenia was present in 56% at day 4, 27% at day 30, and 14.7% at day 365, with G3+ rates remaining high in the first year. G4 lymphopenia affected 48% early on day 4, improving to 15.4% at day 30, then persisting at 11% at day 180 and 15% at day 365. Lymphopenia peaked early, improved over time, but persisted. Neutropenia was delayed, with G3+ rising from 5% at day 30 to 11% at day 90, peaking at 13% around day 223. G4 neutropenia was rare at 1.4% at day 30, with no G4 events at day 365.
Upon further analysis of factors influencing cytopenias, HR cytogenetics were independently associated with G3+ anemia (HR 3.53, 95% CI 1.91-6.54, p<0.001) and thrombocytopenia (HR 6.45, 95% CI 2.71-15.3, p<0.001) on multivariate analysis incorporating pertinent baseline clinical variables. Poor performance status (HR 1.62, 95% CI 1.16-2.27, p=0.005) and higher number of prior ASCT (HR 1.79, 95% CI 1.29-2.48, p<0.001) was also associated with G3+ thrombocytopenia. Prior BCMA-directed therapy trended toward a lower risk of anemia (HR 0.52, 95% CI 0.25-1.05, p=0.068). No baseline variable independently predicted lymphopenia.
Among 165 patients with infection data, 164 infections occurred in 86 patients (52%); 42 patients (25%) had G3+ infection, and one infection was fatal. Predictors of G3+ infection on the following day included G4 neutropenia (HR 3.80, CI 1.70-8.47, p=0.001), G2 anemia (HR 2.83, CI 1.17-6.81, p=0.020), G3+ anemia (HR 8.01, CI 2.33-27.5, p<0.001), G2+ lymphopenia (HR 6.25, CI 2.01-19.4, p=0.002), and G4 thrombocytopenia (HR 3.62, CI 1.02-12.8, p=0.046).
Conclusion: Cytopenias were common in patients receiving BCMA-targeted BsAbs and demonstrated distinct temporal patterns. Anemia and thrombocytopenia occurred early and improved over time, likely reflecting both disease burden and treatment, whereas the lower incidence and delayed neutropenia may have been influenced by supportive care. Lymphopenia was the most significant and persistent cytopenia, with G3+ persisting in approximately 1 in 5 patients in the first 6 months, and about 1 in 7 at 1 year. G2+ lymphopenia was associated with a sixfold increased risk of G3+ infections, consistent with the immune dysfunction associated with BCMA-BsAbs.
DISCLOSURES
Mansi Ramesh Shah, MD: Johnson and Johnson - Honoraria; Pfizer - Honoraria; Bristol Myers Squibb - Honoraria; Regeneron Pharmaceuticals, Inc. - Honoraria; Janssen - Honoraria; Regeneron Pharmaceuticals, Inc. - Research Funding; Abbvie - Research Funding; Johnson and Johnson - Research Funding; Bristol Myers Squibb - Research Funding; Janssen - Research Funding; CellCentric - Research Funding; Pfizer - Consultancy (Includes expert testimony); Targeted Oncology - Consultancy (Includes expert testimony); Regeneron Pharmaceuticals, Inc. - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony)